TY - JOUR
T1 - 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
AU - Singh, Jasvinder A.
AU - Saag, Kenneth G.
AU - Bridges, S. Louis
AU - Akl, Elie A.
AU - Bannuru, Raveendhara R.
AU - Sullivan, Matthew C.
AU - Vaysbrot, Elizaveta
AU - McNaughton, Christine
AU - Osani, Mikala
AU - Shmerling, Robert H.
AU - Curtis, Jeffrey R.
AU - Furst, Daniel E.
AU - Parks, Deborah
AU - Kavanaugh, Arthur
AU - O'Dell, James
AU - King, Charles
AU - Leong, Amye
AU - Matteson, Eric Lawrence
AU - Schousboe, John T.
AU - Drevlow, Barbara
AU - Ginsberg, Seth
AU - Grober, James
AU - St.Clair, E. William
AU - Tindall, Elizabeth
AU - Miller, Amy S.
AU - McAlindon, Timothy
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Objective To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. Results The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (
AB - Objective To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. Results The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (
UR - http://www.scopus.com/inward/record.url?scp=84952639950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952639950&partnerID=8YFLogxK
U2 - 10.1002/art.39480
DO - 10.1002/art.39480
M3 - Article
C2 - 26545940
SN - 2326-5191
VL - 68
SP - 1
EP - 26
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 1
ER -